Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is planned to evaluate the efficacy and safety of secukinumab in Chinese adults with moderate-to-severe hidradenitis suppurativa; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa (HS) | Phase 4 | Status: NOT_YET_RECRUITING